EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Feasibility study of chemotherapeutic efficacy assessment in hyperthermic intraperitoneal chemotherapy (HIPEC)

Ahmed H. Mekkawy, Md Khalilur Rahman, Mohammad Breakeit, Krishna Pillai, Samina Badar, Javed Akhter, Michelle Dietz, Shoma Barat, Sarah J. Valle, David L. Morris

Discover Medicine · 31.07.2026 · 3 (1)

DOI: 10.1007/s44337-026-00632-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Discover Medicine, online erschienen am 31.07.2026. Verfasst von Ahmed H. Mekkawy und 9 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mucpharm Pty Ltd.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

CRS-HIPEC serves as the primary treatment for peritoneal cancers. Although CRS-HIPEC frequently yields positive outcomes, some patients may experience a swift recurrence of cancer. Consequently, a technique to detect any remaining viable tumor cells post-treatment would be advantageous. We propose to explore the feasibility of employing flow cytometry to differentiate viable tumor cells following CRS-HIPEC treatment. Patients and methods During the CRS-HIPEC procedure, peritoneal fluid was collected at two distinct time points: pre-HIPEC perfusion and post-HIPEC. The cells were then concentrated. After in vitro culture, the cells underwent staining. In summary, anti-tumor marker antibodies were used to gate tumor cells. Apoptotic and viable cells were distinguished using Annexin V and Zombie dyes, respectively. Fluorescence minus one (FMO) control were implemented to establish gate boundaries, while unstained cells used as negative controls. A flow cytometer was used for data collection.

Results

This feasibility study encompassed six patients (with colorectal, colorectal, gastric, appendix, appendix, and peritoneum cancers, respectively) who underwent CRS-HIPEC between October and December 2023. Through this feasibility study, we demonstrated that evaluating the efficacy of HIPEC drug on pre- and post-HIPEC samples is achievable. The data indicated an increase in apoptotic cells by 30.6, 13.2, 12.8, 66.1, 3.9, and 8.1%, following HIPEC treatment with MMC, MMC, MMC & Cisplatin, Cisplatin, MMC, and Carboplatin, respectively.

Conclusion

This feasibility study offers initial insights into the capability of a flow cytometry approach to identify and differentiate viable tumor cells from apoptotic and necrotic cells in samples obtained from HIPEC patients.

Förderung

  • Mucpharm Pty Ltd

Zitieren

APA

Mekkawy, A. H., Rahman, M. K., Breakeit, M., Pillai, K., Badar, S., Akhter, J., Dietz, M., Barat, S., Valle, S. J., & Morris, D. L. (2026). Feasibility study of chemotherapeutic efficacy assessment in hyperthermic intraperitoneal chemotherapy (HIPEC). Discover Medicine, 3(1). https://doi.org/10.1007/s44337-026-00632-6

Vancouver

Mekkawy AH, Rahman MK, Breakeit M, Pillai K, Badar S, Akhter J, et al. Feasibility study of chemotherapeutic efficacy assessment in hyperthermic intraperitoneal chemotherapy (HIPEC). Discover Medicine. 2026;3(1). doi:10.1007/s44337-026-00632-6

BibTeX
@article{Mekkawy2026,
  author = {Mekkawy, Ahmed H. and Rahman, Md Khalilur and Breakeit, Mohammad and Pillai, Krishna and Badar, Samina and Akhter, Javed and Dietz, Michelle and Barat, Shoma and Valle, Sarah J. and Morris, David L.},
  title = {Feasibility study of chemotherapeutic efficacy assessment in hyperthermic intraperitoneal chemotherapy (HIPEC)},
  journal = {Discover Medicine},
  year = {2026},
  volume = {3},
  number = {1},
  doi = {10.1007/s44337-026-00632-6}
}
Kostenlos starten →